us patent granted, page-49

abdm,

So we agree that OBJ have not identified many commercial opportunities for their dermaportation technology. That seems unsatisfactory given that this is supposed to be a groundbreaking technology. I think it's because of weak marketing. According to jasetheace30 in another thread, Glyn noted that the team is small, so perhaps the team should be expanded to reach more potential partners. Glyn wrote:

"It is a difficult and protracted road for a small company such as OBJ and a lot of effort is being expended by a very small and dedicated team to hopefully bring to life some form of commercial transaction. We are on the road but not yet reached the destination yet."

Note also that your suggestion that OBJ already has a deal seems to be wrong judging by this quote.